Cellectis S.A. (CLLS): Price and Financial Metrics

Cellectis S.A. (CLLS): $2.82

0.08 (-2.76%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

F

CLLS Price/Volume Stats

Current price $2.82 52-week high $3.77
Prev. close $2.90 52-week low $0.96
Day low $2.74 Volume 17,600
Day high $2.91 Avg. volume 49,177
50-day MA $2.74 Dividend yield N/A
200-day MA $2.47 Market Cap 156.75M

CLLS Stock Price Chart Interactive Chart >


Cellectis S.A. (CLLS) Company Bio


Cellectis SA is a preclinical stage biopharmaceutical company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. The company was founded in 1999 and is based in Paris, France.


CLLS Latest News Stream


Event/Time News Detail
Loading, please wait...

CLLS Latest Social Stream


Loading social stream, please wait...

View Full CLLS Social Stream

Latest CLLS News From Around the Web

Below are the latest news stories about CELLECTIS SA that investors may wish to consider to help them evaluate CLLS as an investment opportunity.

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, resolutions 1 through 5 as well as resolutions 7 and 8 were adopted and resolution 6 was rejected, consistent with the recommenda

Yahoo | December 22, 2023

Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights11/30/202371,751,20177,686,109 For further information on Cellectis, please contact: Media contact: Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, [email protected] Investor Relations contacts: Arthur Stril, Chief Business Off

Yahoo | December 1, 2023

Cellectis’ Shareholders Meeting to be Held on December 22, 2023

NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold a general meeting on December 22, 2023 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. The notice of meeting as published today in the BALO (Bulletin des Annonces Legales Obligatoires), including the a

Yahoo | November 17, 2023

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023.Extraordinary shareholders’ meeting of Cellectis to be held on or around December 22, 2023 to approve such investment. NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that, following the consultation of its works council, it has now signed a binding Subsequent Investm

Yahoo | November 15, 2023

Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript

Cellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call Transcript November 7, 2023 Operator: Good morning, everyone, and welcome to the Cellectis Third Quarter 2023 Earnings Calls. [Operator Instructions]. I’d now like to introduce the first speaker Arthur Stril, Chief Business Officer. You may begin. Arthur Stril: Good morning, and welcome, everyone, to Cellectis third quarter 2023 […]

Yahoo | November 8, 2023

Read More 'CLLS' Stories Here

CLLS Price Returns

1-mo 12.55%
3-mo 3.68%
6-mo -7.54%
1-year 54.10%
3-year -82.00%
5-year -82.95%
YTD -8.44%
2023 46.67%
2022 -74.14%
2021 -69.99%
2020 58.06%
2019 2.82%

Continue Researching CLLS

Want to see what other sources are saying about Cellectis SA's financials and stock price? Try the links below:

Cellectis SA (CLLS) Stock Price | Nasdaq
Cellectis SA (CLLS) Stock Quote, History and News - Yahoo Finance
Cellectis SA (CLLS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!